Preclinical and clinical studies for cardiac cell therapy have only seen moderate success due to poor engraftment and survival of transplanted cells. In this issue of Cell Stem Cell, Ye et al. (2014) employ a growth-factor-loaded fibrin patch and show improved cardiovascular cell survival after cell transplantation into a porcine model of ischemia reperfusion
A major weakness in existing therapies for myocardial infarction is their inability to regenerate th...
abstract: Adult and pluripotent stem cells represent a ready supply of cellular raw materials that c...
Morbidity and mortality from ischaemic heart disease (IHD) and heart failure (HF) remain significant...
Transplantations of various stem cells or their progeny have repeatedly improved cardiac performance...
Contrary to the initial belief that the heart is a terminally differentiated organ that cannot repla...
Functional, stem-cell-containing cardiac grafts will require vascularized myocardial constructs to s...
Abstract Background Application of cardiac stem cells...
SummaryHuman induced pluripotent stem cells (hiPSCs) hold promise for myocardial repair following in...
Heart failure is the number one killer worldwide with ~50% of patients dying within 5 years of prog...
Engineered heart tissue (EHT) strategies, by combining cells within a hydrogel matrix, may be a nove...
Morbidity and mortality from ischaemic heart disease (IHD) and heart failure (HF) remain significant...
Tissue-engineered scaffolds may improve experimental outcomes in cardiac cell therapy by targeted de...
Heart regeneration via stem cell therapy could improve the functional outcome for millions of patien...
© AlphaMed Press. Considerable research has been dedicated to restoring myocardial cell slippage and...
Morbidity and mortality from ischaemic heart disease (IHD) and heart failure (HF) remain significant...
A major weakness in existing therapies for myocardial infarction is their inability to regenerate th...
abstract: Adult and pluripotent stem cells represent a ready supply of cellular raw materials that c...
Morbidity and mortality from ischaemic heart disease (IHD) and heart failure (HF) remain significant...
Transplantations of various stem cells or their progeny have repeatedly improved cardiac performance...
Contrary to the initial belief that the heart is a terminally differentiated organ that cannot repla...
Functional, stem-cell-containing cardiac grafts will require vascularized myocardial constructs to s...
Abstract Background Application of cardiac stem cells...
SummaryHuman induced pluripotent stem cells (hiPSCs) hold promise for myocardial repair following in...
Heart failure is the number one killer worldwide with ~50% of patients dying within 5 years of prog...
Engineered heart tissue (EHT) strategies, by combining cells within a hydrogel matrix, may be a nove...
Morbidity and mortality from ischaemic heart disease (IHD) and heart failure (HF) remain significant...
Tissue-engineered scaffolds may improve experimental outcomes in cardiac cell therapy by targeted de...
Heart regeneration via stem cell therapy could improve the functional outcome for millions of patien...
© AlphaMed Press. Considerable research has been dedicated to restoring myocardial cell slippage and...
Morbidity and mortality from ischaemic heart disease (IHD) and heart failure (HF) remain significant...
A major weakness in existing therapies for myocardial infarction is their inability to regenerate th...
abstract: Adult and pluripotent stem cells represent a ready supply of cellular raw materials that c...
Morbidity and mortality from ischaemic heart disease (IHD) and heart failure (HF) remain significant...